AdvanCell strengthens cancer drug pipeline with $112m Series C funding

AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapy, has successfully completed an oversubscribed $112 million Series C funding round. The investment, co-led by SV Health Investors, Sanofi Ventures, Abingworth, and SymBiosis, marks a significant milestone in the company’s growth and expansion strategy. Additional backing came from existing in